In The News

In The News | December 08, 2017
Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share.
Bloomberg Baystate Business | December 08, 2017
Bloomberg Boston Bureau Chief Tom Moroney and Radio News Anchor Anne Mostue are joined by Quanterix CEO Kevin Hrusovsky to discuss his company’s IPO and first day of trading
The Wall Street Journal | December 08, 2017
Biomarker-analysis company had raised venture capital from ARCH Venture Partners, Bain
The Scientist | December 01, 2017
# 5 Quanterix  |  SR-X Ultra-Sensitive Biomarker Detection System
SelectScience | November 30, 2017
Kevin Hrusovsky is President and CEO of Quanterix, a company that is developing an ultrasensitive immunoassay platform that is capable of detecting very low levels of biomarkers in the body. Watch this exclusive interview to discover Hrusovsky’s vision for the future of healthcare. 
Alzforum | November 17, 2017
Serum NfL levels rise before symptoms appear in familial AD. NfL correlates with cognitive decline and brain atrophy. In MS patients, NfL levels drop with treatment.
Sportsnaut | September 30, 2016
At Powering Precision Health, Robert Stern revealed that Quanterix “has identified elevated levels of tau proteins in blood samples of 96 former football players between 40 and 69 years old, compared with only 25 people of the same age in a control group."
Boston Business Journal | November 21, 2016
Our CEO Kevin Hrusovsky was named one of the Boston Business Journal's 2017 Innovation All-Stars
ScienceDaily | January 6, 2017
Elevated levels of the brain protein tau following concussion are associated with a longer recovery period and may serve as a marker to help physicians determine an athlete's readiness to return to play, report investigators.
News-Medical | February 3, 2017
An interview with Professor David Walt, Tufts University, conducted by April Cashin-Garbutt, MA